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CC BY-NC-ND license (http://creatiAbstract Rupture with internal bleeding is not an uncommon complication of hepatic angio-
sarcomas that causes high morbidity and mortality. Transarterial embolization (TAE) may be
effective for the temporary hemostasis of ruptured tumors. However, the blood supply of an
angiosarcoma can also originate in the portal vein, and repeated internal bleeding may stem
from this source. Elective liver resection following initial TAE is the standard curative treatment
and is the only effective method for preventing further internal bleeding. High-risk liver resec-
tion is the only other choice for rescuing patients with fatal bleeding that cannot be controlled
by TAE. We report a 66-year-old female patient with angiosarcoma who presented with
repeated bleeding and developed hemorrhagic shock after the first episode of TAE. Following
two more episodes of TAE, the patient developed internal bleeding with shock, but angiography
revealed no arterial bleeding. Bleeding from the portal vein was highly suspected. To prevent
further recurrent bleeding, salvage liver resection was subsequently performed under condi-
tions of poor liver reserve. During the 4-month follow-up period until the patient died, no recur-
rent bleeding was noted. In conclusion, TAE is only a temporary treatment for internal bleeding
from a ruptured hepatic angiosarcoma. Recurrent, potentially fatal bleeding may be caused by
supplemental vascularization of the portal vein. Surgical tumor resection is necessary for the
curative treatment of hepatic angiosarcomas and the prevention of repeated internal bleeding.
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Repeated hepatic angiosarcoma bleeding 1291. IntroductionFigure 1 (A) Second bleeding episode: two-phase contrast
computed tomography showing a hypodense hepatic tumor
with hemoperitoneum and extravasation. (B) Second bleeding
episode: angiogram showing previous transarterial emboliza-
tion coil and no extravasation. Arrow headZ extravasation;
AsteriskZ hemoperitoneum; TZ tumor.Angiosarcoma is a rare type of liver cancer that represents
only 2% of primary hepatic malignancies and w4% of all
angiosarcomas of different origins.1 The spontaneous
rupture of a hepatic angiosarcoma may induce severe intra-
abdominal bleeding and is associated with higher morbidity
and mortality.2,3 Transarterial embolization (TAE) may be
effective in obtaining hemostasis in most hepatic malig-
nancies. In most reported cases, TAE has been performed as
the initial treatment. However, ruptured tumors may
induce recurrent internal bleeding and cannot be accessed
by TAE because they are supplemented by multiple blood
sources.2,4 Following TAE with hepatectomy is the only
definite curative treatment available for hepatic angio-
sarcomas; moreover, it can prevent repeated, potentially
fatal internal bleeding. We present a case of ruptured he-
patic angiosarcoma treated by TAE without a subsequent
surgical resection. We identified subsequent recurrent
bleeding that was caused by an angiosarcoma and could not
be controlled by TAE. Successful but risky liver resection
was performed as a salvage treatment to achieve
hemostasis.
2. Case Report
The patient was a 66-year-old woman without previous liver
cirrhosis or any viral hepatitis infection. She worked in a
badminton racket factory where she operated lathes and
recycling planes. The patient had several medical condi-
tions, including rheumatic arthritis, diabetes mellitus, and
hypertension, which were controlled by regular medica-
tion. She developed dull pain in the right upper quadrant
and was referred to a nearby hospital. Medical personnel
noted that the patient was in shock, and she was treated
with fluid resuscitation before being transferred to our
hospital.
The patient had experienced three similar episodes
within the previous 2 months. Initially, she was referred to
a nearby hospital with similar presentation and a ruptured
liver tumor was highly suspected. TAE was performed to
stop the bleeding. Upon admission, according to the pa-
tient, a following tumor resection was not performed
because of the high operative risk. In the following month,
she experienced two similar episodes. Abdominal
computed tomography (CT) revealed one heterogeneous
tumor in the posterior segment, hemoperitoneum, and
contrast extravasation (Figures 1A and 2A). Two angiogra-
phies for TAE showed no active arterial bleeding (Figures
1B and 2B). Conservative treatment was applied in both
episodes.
On arrival, her vital signs were stable. Laboratory data
showed normal hemoglobin levels, low platelet counts
(66,000/mL), elevated international normalized ratio
(1.29), and elevated total bilirubin (1.9 mg/dL). A triphase
abdominal CTwas applied. In the arterial phase (Figure 3A),
a single 16-cm tumor over the right lobe with hemoper-
itoneum was noted but no contrast extravasation was
identified. In the portal vein phase (Figure 3B), some
contrast extravasations were observed in the tumor.
Bleeding from the portal vein was highly suspected.Additionally, multiple smaller nodules were observed in the
right lobe of the liver. After the examination, her vital signs
stabilized with resuscitation and the use of hemostatic
medication; hence, no angiography was performed. The
preoperative indocyanine green (ICGR-15) test adminis-
tered after admission was> 30%. The patient was informed
of the high risk involved in liver resection, and hepatec-
tomy including Segments 6e8 was performed 1 week after
initial presentation to prevent recurrent tumor bleeding.
During the operation, we observed a single huge, pulsating
tumor occupying the right lobe of the liver and presenting
with high vascularity. After the Pringle maneuver was
applied to the main portal vein, the tumor underwent
shrinkage and bleeding decreased. The resected specimen
consisted of a 16 cm 8.5 cm 7.2 cm mass. The
morphological image revealed a ruptured hepatic angio-
sarcoma. The resection margin was tumor free.
Figure 2 (A) Third bleeding episode: two-phase contrast
computed tomography showing a hypodense hepatic tumor
with hemoperitoneum and extravasation. (B) Third bleeding
episode: angiogram showing previous transarterial emboliza-
tion coil and no extravasation. Arrow headZ extravasation;
AsteriskZ hemoperitoneum; TZ tumor. Figure 3 (A) Fourth bleeding episode (in our hospital): arterial
phase of a three-phase contrast computed tomography showing a
hypodense hepatic tumor with hemoperitoneum but no extrava-
sation. (B) Fourth bleeding episode (in our hospital): portal phase
of a three-phase contrast computed tomography showing a
hypodense hepatic tumor, hemoperitoneum, and extravasation.
Arrow headZ extravasation; AsteriskZ hemoperitoneum;
TZ tumor.
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ascites of> 1 L/d were identified 3 days postoperation.
Liver decompensation was noted. After conservative
treatment, bilirubin levels and the amount of ascites
gradually decreased. The patient was discharged 33 days
postoperation. However, newly developed intrahepatic le-
sions and lung lesions were noted 1 month after discharge.
No further salvage treatments were applied and the patient
chose hospice care. The patient died 3 months later as a
result of cancer progression. During the 4-month follow-up
period, no further internal bleeding episodes were noted.
3. Discussion
Hepatic angiosarcoma remains the third most common
primary liver malignancy and the most common malignant
mesenchymal liver tumor.1 Its reported annual incidence is
0.26 per million population and mortality is w0.075 casesper million population, with a strong male predomi-
nance.5,6 It often occurs in elderly patients, particularly
those in their 60s and 70s.7 Previous reports have associated
this malignancy with environmental carcinogens, yet most
cases currently reported are unrelated to these reported
factors or have unknown etiology.6 Hepatic angiosarcoma
originates in masses of endothelial cells. Over 70% of he-
patic angiosarcoma patients have multifocal lesions. When
the normal liver parenchyma is replaced by a tumor, it may
cause liver decompensation, including ascites and jaun-
dice, and even fulminant hepatic failure.8 Poor prognosis
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have shown that the median survival of patients is only 6
months without treatment; even after treatment, only 3%
of them live longer than 2 years.9 Surgical resection is the
standard treatment for hepatic angiosarcoma. Currently,
there are no effective adjuvant therapies after surgery
including radiation therapy or chemotherapy.6
Hepatic angiosarcomas spontaneously rupture in w27%
of patients. This may induce severe intra-abdominal
bleeding, and is associated with high morbidity and mor-
tality.3 Spontaneous rupture leads to tumor cell spillage
and peritoneal seeding, which may compromise prognosis.2
TAE has been the primary procedure used to control
hemoperitoneum resulting from tumor rupture.2 However,
this is not effective for all hepatic angiosarcoma patients;
possibly because the condition can involve different blood
supplies. Some reports have shown that angiosarcoma
might be supplied both by the portal vein and by the he-
patic artery. The tumor may originate near cells that form
in abnormal vascular spaces that continuously infiltrate the
dilated sinusoids and, in certain cases, connect with the
portal vein.4 In our case, the hepatic artery was throm-
bosed by TAE when bleeding first occurred. However,
repeated bleeding episodes were noted, and no active
bleeding was observed in the angiograph. This indicates
portal venous bleeding via abnormal spaces and dilated
sinusoids. The only method of preventing such a condition is
surgical resection of the tumor.
Early diagnosis and complete surgical resection appear
to be the only methods of curing hepatic angiosarcoma.6
However, major hepatectomy remains risky, particularly
in cirrhotic patients. Fan10 mentioned that major hepa-
tectomy is unsafe when ICGR-15 levels are> 14%. In the
case of our patient, her preoperative ICGR-15 was> 30%,
but she was noncirrhotic and did not present with hepatitis.
Although she was at a high risk for postoperative mortality,
we still performed this salvaging hepatectomy to prevent
further bleeding. After surgery, liver dysfunction was
noted, but the patient recovered smoothly. We were con-
cerned that preoperative liver function might be impaired
by the tumor occupying the normal liver parenchyma, but
the residual liver was relatively healthy. The regeneration
of residual normal liver tissue helped her survive post-
operative liver decompensation. Because there were no
viable alternatives, we concluded that major hepatectomy
should be performed, because it is an extensive indication
for such a patient with ruptured hepatic angiosarcoma and
without obvious signs and symptoms of cirrhosis.
In summary, TAE is only a temporary treatment for in-
ternal bleeding from a ruptured hepatic angiosarcoma.
Although a poor prognosis was suspected because of the
ruptured, aggressive tumor, it was decided that surgery
should be performed as soon as possible. Surgical tumorresection is necessary to definitively treat hepatic angio-
sarcoma. If it is not performed, supplemental vasculariza-
tion of the portal vein may induce recurrent, potentially
fatal internal bleeding.3.1. Informed consent
Informed consent was obtained by telephone from the
family of the patient, allowing for the publication of this
case report and any accompanying images. A copy of the
written consent form is available for review by the editor-
in-chief of this journal.Acknowledgments
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